All news

(Image: Getty/Milkos)

BIO-Europe Spring

Finding treatment solutions where there are none

By Ben Hargreaves

The industry focuses investments where there is the highest potential returns, but one panel at BIO-Europe Spring suggested multiple partners could boost outcomes in underserved therapeutic areas.

(Image: Getty/Ktsimage)

Regeneron in $1bn RNAi pact with Alnylam

By Ben Hargreaves

Regeneron and Alnylam sign discovery agreement that could advance 30 targets within CNS and ocular disorders, during an initial five-year discovery period.